These findings underscore that bacterial platforms expressing GLP-1 with controlled release can serve as an effective basis for long-term and physiologically coordinated diabetes therapy, while also highlighting the gut environment as a therapeutic target. Here, GLP1R is linked to diabetes mellitus.